Lithium price squeeze hits Pilbara as spodumene rally fades

Pilbara Minerals, the ASX-listed lithium producer that owns the Pilgangoora hard-rock operation, reported revenue of $1.254 billion for FY24. That is up 92.5% per year since 2021. Net profit swung from a $51 million loss to $257 million over the same stretch.

The headline numbers mask a shift underway. The global price of spodumene concentrate has fallen sharply from its 2022 peaks. Pilbara sells its lithium-bearing rocks through long-term offtake agreements with Great Wall and POSCO, and through spot sales on its Battery Material Exchange. The spot channel has seen prices soften, a sign the market is rebalancing after a period of tight supply.

Return on equity came in at 7.7% for the year. That figure lags the broader materials sector. It reflects the capital intensity of the hard-rock mining model, where large upfront investment in crushing and processing infrastructure must be recovered before margins widen.

Volume growth has been strong. The company shipped 707,000 dry metric tonnes of spodumene concentrate in FY24, up from 406,000 the prior year. But the revenue benefit was partly offset by lower realised prices. Pilbara's average selling price for the year was $1,176 per tonne, down from $1,912 in FY23.

Analysts following the stock point to the company's cost position as a buffer. Pilbara reports C1 cash costs of $659 per tonne, among the lowest in the industry. That gives it room to operate profitably even if prices fall further. The risk is margin compression, not a cash burn.

The broader lithium market is in a transition phase. Electric vehicle adoption continues to grow, but the pace of growth has slowed in key markets like China. Meanwhile, new supply from projects in Africa and South America is coming online. The result is a market that looks adequately supplied for the near term.

Pilbara's long-term offtake agreements provide some revenue visibility. Great Wall and POSCO have committed to purchasing minimum volumes through 2026. But the pricing terms are linked to market benchmarks, so the company still has direct exposure to the spot price.

For investors, the key question is whether the current softness is a cyclical pause or a structural change. If EV demand reaccelerates and new supply disappoints, the current price weakness could be temporary. If supply additions continue to outpace demand growth, Pilbara may need to rely on its cost advantages and volume growth to offset lower prices.

The company's growth rate has already slowed. Revenue tripled between FY21 and FY23, then grew 38% in FY24. At the current run rate, triple-digit growth is off the table. The question is whether high-teens growth is sustainable.

A comparison with Pro Medicus, which reported FY24 revenue of $162 million and an ROE of 50.7%, illustrates how different business models generate different returns. Pilbara's growth has been spectacular, but its capital intensity and commodity price exposure mean the returns are less predictable.

Pilbara's next catalyst is the March quarter production report, due in April. Investors will be watching the average realised price and any commentary on forward demand from offtake partners. The company also has a downstream processing joint venture with POSCO in South Korea, which could provide a route to higher margins if lithium hydroxide prices recover.

For now, the story is about whether Pilbara can maintain growth as the price cycle turns. The company has volume and cost advantages. But the market is pricing in a slower trajectory, and the numbers support that view.